Johnson & Johnson SURGICAL — Sales to customers (Note 9) decreased by 5.3% to $765.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 14.9%, from $666.00M to $765.00M. Over 2 years (FY 2021 to FY 2024), SURGICAL — Sales to customers (Note 9) shows an upward trend with a 23.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growing market adoption or successful product launches within the surgical portfolio, while a decrease may signal competitive pressure or reduced demand for surgical procedures.
This metric represents the total revenue generated from the sale of surgical products and medical devices to external cu...
Comparable to segment-specific net revenue figures reported by other diversified medical device and healthcare conglomerates.
jnj_segment_surgical_sales_to_customers_note_9| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $576.00M | $628.00M | $616.00M | $627.00M | $694.00M | $694.00M | $596.00M | $694.00M | $656.00M | $696.00M | $734.00M | $666.00M | $730.00M | $721.00M | $808.00M | $765.00M |
| QoQ Change | — | +9.0% | -1.9% | +1.8% | +10.7% | +0.0% | -14.1% | +16.4% | -5.5% | +6.1% | +5.5% | -9.3% | +9.6% | -1.2% | +12.1% | -5.3% |
| YoY Change | — | — | — | — | +20.5% | +10.5% | -3.2% | +0.0% | -5.5% | — | +5.8% | +1.5% | — | +3.6% | +10.1% | +14.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.